OG-L002

Catalog No.S7237 Batch:S723701

Print

Technical Data

Formula

C15H15NO
Molecular Weight 225.29 CAS No. 1357302-64-7
Solubility (25°C)* In vitro DMSO 45 mg/mL (199.74 mM)
Ethanol 19 mg/mL (84.33 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG 300 5%Tween80 50% ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 1.000mg/ml (4.44mM) Taking the 1 mL working solution as an example, add 50 μL of 20 mg/mL clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify; add 50 μL Tween-80 to the above system, mix evenly to clarify; Then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM in a cell-free assay, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.
Targets
LSD1 [1]
(Cell-free assay)
20 nM
In vitro TCN 201 partially inhibits the NMDA-induced intracellular Ca2+ response in a concentration-dependent manner with a pIC50 of 6.4. TCN 201 partially inhibits [3H]CGP 39653 specific binding showing a maximal radioligand displacement of 44%, respectively, and a pIC50 of 6.5. TCN 201 at a concentration of 10 μM does not protect against Tat-induced cell death, in contrast to ifenprodil and memantine. However, this same concentration of TCN 201 prevents Tat-induced synapse loss. TCN 201 inhibits synapse recovery after Tat-induced loss. TCN 201 demonstrates potent but GluN1 co-agonist concentration-dependent inhibition of GluN1/GluN2A NMDAR-mediated responses. TCN 201 causes substantially less inhibition of the TEVC current trace. TCN 201 is around 30-times more potent than TCN 213. In cortical neurones TCN 201 shows only modest antagonism of NMDAR-mediated currents recorded from young (DIV 9-10) neurones where GluN2B expression predominates. In older cultures (DIV 15-18) or in cultures where GluN2A subunits have been over-expressed TCN 201 gives a strong block that is negatively correlated with the degree of block produced by the GluN2B-selective antagonist, ifenprodil. TCN-201 binds to a novel allosteric site located at the dimer interface between the GluN1 and GluN2 agonist binding domains.
In vivo

OG-L002 (6 to 40 mg/kg) represses HSV primary infection in a dose-dependent manner in a mouse model. Moreover, this compound also represses HSV reactivation from latency in a mouse ganglion explant model.

Features This selective LSD1 inhibitor was discovered in 2013. Potential for use in viral diseases such as HSV and VZV.

Protocol (from reference)

Kinase Assay:

[1]
  • LSD1 demethylation assay

    The demethylase activity is measured by the release of H2O2 produced during the catalytic process, using the Amplex red peroxide/peroxidase-coupled assay kit. Each reaction is done in triplicate. The maximum LSD1 demethylase activity is obtained in the absence of inhibitor and corrected for background fluorescence. The Ki (IC50) of this compound is calculated as half-maximal activity.
Cell Assay:

[1]
  • Cell lines

    HeLa and HFF cells

  • Concentrations

    ~50 μM

  • Incubation Time

    12 hours

  • Method

    HeLa or HFF cells are treated with the indicated concentrations of saponin (positive control) or compound OG-L002 for 12 hours. Cytotoxicity is determined using conditions recommended by the manufacturer and expressed as ratios to the cytotoxicity of the DMSO control.
Animal Study:

[1]
  • Animal Models

    BALB/c female mice are infected with HSV-2 (strain MS).

  • Dosages

    ~50 mg/kg

  • Administration

    Intraperitoneal administration

References

  • https://pubmed.ncbi.nlm.nih.gov/23386436/

Customer Product Validation

Nalm6 cells were first treated with JIB-04 at 0.5 μM, OG-L002 at 10 μM or DMSO for 4 h, then 100 nM of dex or ethanol was added to the media for an additional 20 h. Lysates were analyzed by immunoblot with the indicated antibodies. Results shown are representative of three independent experiments.

Data from [ , , Cell Death Dis, 2018, 9(10):1038 ]

Effect of treatment on equine herpesvirus type 1 (EHV-1) viral load during lytic infection of primary equine fetal kidney cells. At 24 hpi, reduced EHV-1 DNA copies per cell were detected in the presence of ganciclovir (**p = 0.0005) or OG-L002 (*p = 0.005), and markedly when both treatments (***p < 0.0001) were applied simultaneously in comparison with DMSO control vehicle. Combined treatment decreased the number of EHV-1 DNA copies in comparison to treatment with ganciclovir alone (p = 0.01) or OG-L002 alone (p = 0.001). Lines represent mean values.

Data from [ , , Front Vet Sci, 2018, 5:34 ]

Hepa1c1c7 cells were seeded in 6 well plates. The following day, cells were treated with either 100 nM of Dex for 1 hours, 5mM of VPA for 2 hours, the respective LSD1 inhibitor, or a combination. In terms of LSD1 inhibitor treatment, cells were dosed with 50 uM (Ampd3) or 100 uM (Hbegf) of OG-L002 for 24 hours. Cells were then harvested, and isolated RNA underwent RT-qPCR using intron-exon primers to measure expression of nascent transcripts. For each of the LSD1 inhibitors used, a representative GR activated (Ampd3) and repressed (Hbegf) gene was analyzed. Error bars represent SEM. Statistical analysis using a paired t test was performed, but none of the results demonstrated significance.

Data from [ , , The University of Arizona, 2016 ]

Selleck's OG-L002 Has Been Cited by 20 Publications

Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas [ Cancer Res Commun, 2025, 5(9):1584-1598] PubMed: 40852926
N'-(1-phenylethylidene)-benzohydrazide cytotoxicity is LSD1 independent and linked to Fe-S cluster disruption in Ewing sarcoma [ bioRxiv, 2025, 2025.06.20.660795] PubMed: 40666939
Potential role of lipophagy impairment for anticancer effects of glycolysis-suppressed pancreatic ductal adenocarcinoma cells [ Cell Death Discov, 2024, 10(1):166] PubMed: 38580661
Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins [ bioRxiv, 2024, 2024.05.19.594897] PubMed: 38826330
Evaluation of Histone Demethylase Inhibitor ML324 and Acyclovir against Cyprinid herpesvirus 3 Infection [ Viruses, 2023, 15(1)163] PubMed: 36680202
LSD1-mediated demethylation of OCT4 safeguards pluripotent stem cells by maintaining the transcription of PORE-motif-containing genes [ Sci Rep, 2021, 11(1):10285] PubMed: 33986438
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer [ Nat Genet, 2020, 52(10):1011-1017] PubMed: 32868907
Targeted DNA oxidation by LSD1-SMAD2/3 primes TGF-β1/ EMT genes for activation or repression [ Nucleic Acids Res, 2020, gkaa599] PubMed: 32697292
Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. [ Sci Rep, 2020, 10(1):377] PubMed: 31941995
Hdac1 Regulates Differentiation of Bipotent Liver Progenitor Cells During Regeneration via Sox9b and Cdk8. [ Gastroenterology, 2019, 156(1):187-202] PubMed: 30267710

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.